Health Care·Pharmaceuticals·$2.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.54 | N/A | +6.90% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.54 | N/A | +6.90% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed a commitment to their strategic goals despite the lack of revenue guidance. They emphasized the importance of their ongoing projects.
We are focused on our strategic initiatives moving forward.
Our team remains dedicated to advancing our pipeline.
Enliven Therapeutics reported a narrower-than-expected loss per share, which was a positive surprise. However, the stock fell by 2.53%, likely due to the absence of revenue figures and guidance. Investors may be cautious as the company continues to navigate its strategic initiatives without clear financial targets.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
D-WAVE QUANTUM INC
May 13, 2024